The second dose of the Chinese Communist Party (CCP) Virus (COVID-19) vaccine, produced by AstraZeneca and the University of Oxford, must not be given to anyone who has had blood clots or low blood platelets after obtaining the first shot, according to the European Medicines Agency.
The European medicines regulator made the statement on Friday, May 21, Reuters reported.
Many European nations started to reconsider its use in all age groups only after a few reports of unusual blood-clotting disorders—several fatal—arose during the last month.
Data provided by EudraVigilance shows that there have been 5,698 cases of blood and lymphatic system disorder, ranging from 18 to 64 years old as of May 22.
The European Medicines Agency (EMA) on May 21 issued additional guidance to healthcare professionals as part of an ongoing investigation into rare but serious blood clots related to the inoculation of the Vaxzevria (formerly AstraZeneca vaccine) and Johnson & Johnson vaccines.
In its report, the Human Medicines Committee (CHMP) of EMA announced that:
- Vaxzevria should not be given to someone who has had blood clots or low blood platelets after receiving the vaccine (thrombosis with thrombocytopenia syndrome, TTS).
- Within 3 weeks of vaccination, anyone with low blood platelets should be checked for signs of blood clots.
- Any individual who has blood clots within 3 weeks of vaccination should be checked for signs of low blood platelets.
- Patients with blood clots and low blood platelets following vaccination should be treated by a healthcare specialist.
For several weeks now, health organizations in Europe have been exposing a clear correlation between people who were inoculated with the AstraZeneca vaccine and then suffered rare blood clots that in many cases ended in the death of the patient.
Marco Cavaleri, chairman of the EMA’s vaccine evaluation team, confirmed to the newspaper Il Messaggero when asked about the possible link between the AstraZeneca injection and the cases of blood clots in the brain, that: “In my opinion, we can now say it, it is clear that there is an association with the vaccine. However, we still don’t know what causes this reaction,” Reuters reported.
The vaccine expert explained that among those vaccinated with AstraZeneca, there is “a higher than expected number of cases of cerebral thrombosis with platelet deficiency among young people.” He also pointed out that young women are “protagonists of thrombosis cases.”
Several countries have discontinued the AstraZeneca vaccine for recording severe adverse effects in a high percentage of inoculated patients. Denmark, Iceland, Norway, Bulgaria, and Thailand were among them. France, Italy, and Germany also momentarily suspended vaccination campaigns with AstraZeneca, although they decided to continue after receiving assurances from the EMA and the World Health Organization.